Trials / Completed
CompletedNCT00032903
This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Malignant Glioma.
Oral ST1481 in Adults With Malignant Glioma: a Phase I-II Clinical Trial
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 59 (estimated)
- Sponsor
- Sigma-Tau Research, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Gimatecan® is Sigma-Tau Research's new, potent, oral Topoisomerase I inhibitor. Drugs in this class play a crucial role in destroying DNA replication in tumors. We are conducting this study to determine the Maximum Tolerated Dose of our compound. In addition, we plan to assess the drug's ability to affect the evolution of malignant gliomas, when given as a capsule, rather than by intravenous injection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gimatecan® (ST 1481) |
Timeline
- Start date
- 2002-03-01
- Completion
- 2005-10-01
- First posted
- 2002-04-08
- Last updated
- 2009-06-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00032903. Inclusion in this directory is not an endorsement.